Moderna lays out plan for mRNA-1273 vaccine

By The Science Advisory Board staff writers

May 19, 2020 -- Moderna released interim clinical data about mRNA-1273, its vaccine candidate against SARS-CoV-2, from the phase I study led by the U.S. National Institute of Allergy and Infectious Diseases (NIAID). Based on the results, the company plans to begin a phase III study in July.

In the phase I study, patients were dosed at 25 µg or 100 µg; all participants seroconverted by day 15 after a single dose. Researchers found that mRNA-1273 vaccination-neutralizing antibody titers in eight patients exceeded those seen in convalescent sera. Moreover, the vaccine was generally safe and well-tolerated by participants.

In the phase II study, the company will amend the dose levels, at 50 µg and 100 µg, with the goal of selecting a pivotal dose. The NIAID-led phase I study is also amending doses to include a 50 µg dose level cohort across three age groups.

Phase II and III studies of mRNA-1273 are supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA). They are also supporting the scale-up of mRNA-1273 manufacturing at two Moderna facilities as well as at Lonza facilities, a strategic partner of the company.

BARDA gives $20M to Sabin Vaccine Institute for vaccines
The U.S. Biomedical Advanced Research and Development Authority (BARDA) awarded the Sabin Vaccine Institute $20 million to manufacture and release...
NIH leadership discusses COVID-19 vaccine collaborations
Public-private partnerships could help meet the unprecedented need to manufacture and distribute safe and effective COVID-19 vaccines around the globe,...
Experts discuss promising strategies for tackling SARS-CoV-2
What's the best strategy for developing treatments for the SARS-CoV-2 virus? The most promising approaches for a rapid response are antivirals and gene...
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...
NIAID announces new COVID-19 priorities
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) has released a new strategic plan for accelerating research to diagnose, prevent,...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter